Pathfinder Cell Therapy (OTCMKTS:PFND – Get Free Report) and ReWalk Robotics (NASDAQ:LFWD – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Pathfinder Cell Therapy and ReWalk Robotics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pathfinder Cell Therapy | 0 | 0 | 0 | 0 | N/A |
ReWalk Robotics | 0 | 0 | 1 | 1 | 3.50 |
ReWalk Robotics has a consensus target price of $13.00, indicating a potential upside of 219.41%.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Pathfinder Cell Therapy | N/A | N/A | N/A |
ReWalk Robotics | -134.52% | -35.41% | -27.64% |
Earnings & Valuation
This table compares Pathfinder Cell Therapy and ReWalk Robotics’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pathfinder Cell Therapy | N/A | N/A | N/A | N/A | N/A |
ReWalk Robotics | $13.85 million | 2.56 | -$22.13 million | ($3.11) | -1.31 |
Pathfinder Cell Therapy has higher earnings, but lower revenue than ReWalk Robotics.
Insider and Institutional Ownership
26.8% of ReWalk Robotics shares are held by institutional investors. 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Comparatively, 2.1% of ReWalk Robotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
About Pathfinder Cell Therapy
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Receive News & Ratings for Pathfinder Cell Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pathfinder Cell Therapy and related companies with MarketBeat.com's FREE daily email newsletter.